Added to YB: 2026-01-13
Pitch date: 2026-01-09
GSK [bullish]
GSK plc
-0.13%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 75.7B
Pitch Price
GBP 18.80
Price Target
N/A
Dividend
3.23%
EV/EBITDA
9.22
P/E
14.19
EV/Sales
2.79
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 9/1/2026 - GSK – Pipeline progress
GSK (update): China approves Nucala for COPD (30% of global mortality market), Japan approves depemokimab for asthma/rhinosinusitis, EU approval imminent. Positive Phase III bepirovirsen results for chronic hep-B (250M+ patients), filings planned Q1 2026. 62 pipeline assets undervalued at 9.5x 2027 P/E, 3.8% yield.
Read full article (1 min)